sotrovimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiviral, monoclonal antibodies	5505	2423014-07-5

Description:

Molecule

Description

Synonyms:

sotrovimab
sotrovimab (genetical recombination)
xevudy
VIR-7831
GSK4182136

Sotrovimab is a human IgG1 mAb that binds to a highly conserved epitope on the spike protein receptor binding domain of SARS-CoV-2.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 17, 2021	EMA	GLAXOSMITHKLINE TRADING SERVICES LIMITED
Sept. 27, 2021	PMDA	GLAXOSMITHKLINE K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	2149.72	48.71	537	1220	155010	63332255
Infusion related reaction	217.64	48.71	114	1643	245407	63241858

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	235.43	42.48	80	1002	52977	34902872
Chills	54.98	42.48	33	1049	81010	34874839
Oxygen saturation decreased	50.18	42.48	27	1055	53791	34902058
COVID-19 pneumonia	49.87	42.48	19	1063	16948	34938901

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	1896.81	41.93	481	2485	100651	79640771
Infusion related reaction	435.43	41.93	197	2769	230040	79511382
COVID-19 pneumonia	102.45	41.93	39	2927	28810	79712612
Oxygen saturation decreased	74.69	41.93	51	2915	128996	79612426
Chills	52.19	41.93	45	2921	160189	79581233
Infusion site extravasation	48.22	41.93	17	2949	10091	79731331

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J06BD05	ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
COVID-19	indication	840539006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Spike glycoprotein	Glycoprotein		SPIKE_SARS2	BINDING AGENT	Kd	9.68		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4650524	ChEMBL_ID
C000711967	MESH_SUPPLEMENTAL_RECORD_UI
11333	IUPHAR_LIGAND_ID
DB16355	DRUGBANK_ID
018751	NDDF
4040549	VANDF
D12014	KEGG_DRUG
C5433947	UMLSCUI
11766	INN_ID
1162689008	SNOMEDCT_US
1162693002	SNOMEDCT_US
2550731	RXNORM
346571	MMSL
39535	MMSL
d09747	MMSL
1MTK0BPN8V	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sotrovimab	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0901	INJECTION, SOLUTION, CONCENTRATE	62.50 mg	INTRAVENOUS	Unapproved drug other	29 sections
Sotrovimab	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0901	INJECTION, SOLUTION, CONCENTRATE	62.50 mg	INTRAVENOUS	Unapproved drug other	29 sections
Sotrovimab	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0901	INJECTION, SOLUTION, CONCENTRATE	62.50 mg	INTRAVENOUS	Unapproved drug other	29 sections